Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for central nervous system (CNS) disorders, particularly major depressive disorder (MDD). Its lead candidate, esmethadone (REL-1017, d-methadone), is an NMDA receptor channel blocker being developed as a rapid-acting antidepressant. The company also has programs in psilocybin and other CNS indications.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2026
Create a free account to see which investors have funded this company.
Create Free Account
BridgeBio Pharma is a clinical-stage biopharmaceutical company developing therapies for genetic d...
Clinical-stage biopharmaceutical company developing FcRn inhibitor therapies for IgG-mediated aut...
Commercial-stage oncology company pioneering antibody drug conjugate therapies for cancer treatment.
Global clinical-stage biopharmaceutical company pursuing novel drug development platforms for rar...
Research-based development stage biopharmaceutical company that discovers and develops innovative...
Clinical-stage biopharmaceutical company developing T cell receptor-based adoptive cell therapies...
